Revenue grew 44% year-over-year to $335.0 million in Q2 2026, driven by strong oncology and screening test volume growth, while net loss widened to $120.1 million due to increased R&D and commercial investments. Cash reserves remain robust at $1.2 billion, supporting ongoing expansion and innovation.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.